HERTFORDSHIRE, England and
PITTSBURGH, May 1, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ,
TASE: MYL) today announced that its Board of Directors has
nominated Sjoerd S. Vollebregt as a
candidate for election to Mylan's Board at the 2017 Annual Meeting
of Shareholders to be held on June 22,
2017. The Board also announced that directors Douglas J. Leech, Joseph
C. Maroon and Rodney L. Piatt
will retire from the Board effective June 22, 2017 and
have not been nominated for reelection at the Annual Meeting. If
Mylan's shareholders elect all candidates nominated by the Board at
the Annual Meeting, including Vollebregt, Mylan's Board will
consist of 11 directors, eight of whom will be
independent.
Mylan Chairman Robert J. Coury
commented: "On behalf of the entire Board of Directors I want to
thank Doug, Joe and Rod for their many years
of outstanding service to all of our stakeholders and
leadership on the Mylan Board, as well as for their significant
contributions to the company, its strategic development and strong
growth."
Mr. Coury continued, "As Mylan continues its evolution as a
leading global healthcare company, we will continue to seek out
additional candidates who can further strengthen our
Board by bringing fresh perspectives that can add to our Board's
already broad diversity and experience. Nominating Sjoerd
accomplishes just that. He brings to Mylan a phenomenal breadth of
leadership experience across a variety of industries and a new,
independent perspective on how to maximize the many potential
opportunities we see ahead for our company. He also brings a
strong history of prior senior level executive
management experience and currently serves on the boards of
directors of other Dutch companies."
Vollebregt currently serves as the chairman of the Supervisory
Board of Heijmans N.V., a Euronext Amsterdam listed company
operating in property development, residential building,
non-residential building, roads and civil engineering, and as
chairman of the Advisory Board of Airbus Defence and Space
Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris
listed company, that develops solar arrays, satellite instruments
and structures for launchers. Previously, Vollebregt served as
chairman of the Executive Board of Stork B.V., an Amsterdam Stock
Exchange-listed industrial group, and as chief executive officer of
Fokker Technologies Group B.V., an aerospace company and a Stork
B.V. subsidiary. Vollebregt also has previously served as a member
of the Supervisory Board of TNT Express N.V., an international
courier delivery services company, and has held various other
senior positions at Exel plc, Ocean plc, Intexo Holding and
Royal Van Ommeren.
Vollebregt said, "I am honored to have been nominated for
election to the Mylan N.V Board. I have had the privilege and
opportunity to spend a great deal of time in getting to know Mylan,
its Board of Directors and management team, and, if elected, I am
very confident that I will be able to contribute to this strong,
dynamic group of leaders. Mylan has an extraordinarily rich history
of growth and success, and has truly differentiated itself in the
global pharmaceutical industry in its quest to benefit
shareholders and all other stakeholders."
This press release includes statements that constitute
"forward-looking statements." These statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and include statements about how Mylan continues
to evolve into a leading global healthcare company and about
maximizing the many opportunities Mylan sees ahead for itself.
Because forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such statements. Factors that could
cause or contribute to such differences include, but are not
limited to any changes in, interruptions to, or difficulties with
Mylan's or its partners' ability to develop, manufacture, and
commercialize products; the effect of any changes in Mylan's or its
partners' customer and supplier relationships and customer
purchasing patterns; other changes in third-party relationships;
the impact of competition; changes in the economic and financial
conditions of the businesses of Mylan or its partners; the scope,
timing, and outcome of any ongoing legal proceedings and the impact
of any such proceedings on Mylan's or its partners' business; any
regulatory, legal, or other impediments to Mylan's or its partners'
ability to bring products to market; actions and decisions of
healthcare and pharmaceutical regulators, and changes in healthcare
and pharmaceutical laws and regulations, in the United
States and abroad; Mylan's and its partners' ability to
protect intellectual property and preserve intellectual property
rights; risks associated with international operations; other
uncertainties and matters beyond the control of management; and the
other risks detailed in Mylan's filings with the Securities and
Exchange Commission. Mylan undertakes no obligation to update these
statements for revisions or changes after the date of this
release.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We market a
growing portfolio of approximately 7,500 products around the world,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS in the developing world depend.
We market our products in more than 165 countries and territories.
We are one of the world's largest producers of active
pharmaceutical ingredients. Every member of our more than
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at
mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-nominates-sjoerd-vollebregt-for-election-to-board-of-directors-300448605.html
SOURCE Mylan N.V.